Oslo, December 13, 2016 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, reported today that the undisclosed top-10 pharma company has notified PCI Biotech that they intend to extend the existing research collaboration agreement, originally signed in September 2015, until the end of 2Q 2017. The aim of the extension is to further evaluate the synergistic effects of both parties’ technology platforms, to determine whether PCI Biotech’s fimaNAc technology has the potential to enhance the therapeutic effect of the partner’s nucleic acid therapeutic compounds.
The pre-clinical research agreement covers evaluation of technological compatibility and synergy based on in vitro studies. The pharma company is one of the global leaders in nucleic acid therapeutics and is responsible for funding and conducting the research. The companies will evaluate the data generated in this research collaboration and explore the potential for a further partnership based on this outcome. The extended evaluation period spans over six months, but may be further extended.
Skjer det noe her de nærmeste dagene, tro?
